financetom
Market
financetom
/
Market
/
Conference Board's Leading Indicators Index rises for first time in 2 years
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Conference Board's Leading Indicators Index rises for first time in 2 years
Mar 21, 2024 8:50 AM

March 21 (Reuters) - The Conference Board said on

Thursday its Leading Economic Index for the United States rose

last month for the first time in two years on the strength of

hours worked at U.S. factories and the surging stock market,

among other factors, but the gauge of future activity still

signals some headwinds to growth remain.

The business research group's index rose 0.1% in February to

102.8, exceeding estimates in a Reuters poll of economists for a

decline of 0.2%. It was the first increase in the index since

February 2022 and comes a month after the organization abandoned

its prediction that the economy would fall into a recession.

Justyna Zabinska-La Monica, senior manager for Business

Cycle Indicators, said the Conference Board's credit gauge and

residential construction also helped drive the index higher, but

measures of consumer expectations and new orders for U.S.

manufacturers have yet to recover.

"Despite February's increase, the Index still suggests

some headwinds to growth going forward," she said. "The

Conference Board expects annualized US (gross domestic product)

growth to slow over the Q2 to Q3 2024 period, as rising consumer

debt and elevated interest rates weigh on consumer spending."

An Atlanta Fed model tracking U.S. economic growth

currently sees first-quarter output rising at a 2.1% annualized

rate, down from 3.2% in the fourth quarter of 2023, but still

above the 1.8% rate that Fed policymakers see as the economy's

long-term potential.

Fed officials, in fact, on Wednesday raised their

estimates for GDP growth this year to 2.1% from 1.4% as

projected in December. Growth estimates for the next two years

were also revised higher.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sector Update: Tech
Sector Update: Tech
Jun 20, 2024
08:54 AM EDT, 06/20/2024 (MT Newswires) -- Technology stocks were edging higher pre-bell Thursday with the Technology Select Sector SPDR Fund (XLK) marginally advancing and the SPDR S&P Semiconductor ETF (XSD) up 0.3% recently. The UK's Competition and Markets Authority said it is launching a probe of Hewlett-Packard's ( HPE ) $14 billion acquisition of Juniper Networks (JPNR). Hewlett Packard...
NVIDIA Stock Gains Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday
NVIDIA Stock Gains Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Thursday
Jun 20, 2024
08:15 AM EDT, 06/20/2024 (MT Newswires) -- The broad market exchange-traded fund SPDR S&P 500 ETF Trust ( SPY ) was up 0.4% and the actively traded Invesco QQQ Trust (QQQ) was 0.6% higher in Thursday's premarket activity pushed by the continued gains in NVIDIA's ( NVDA ) stock. US stock futures were mixed, with S&P 500 Index futures up...
Sector Update: Financial
Sector Update: Financial
Jun 20, 2024
09:01 AM EDT, 06/20/2024 (MT Newswires) -- Financial stocks were edging higher pre-bell Thursday with the Financial Select Sector SPDR Fund (XLF) 0.02% higher recently. The Direxion Daily Financial Bull 3X Shares (FAS) was up 0.5% and its bearish counterpart Direxion Daily Financial Bear 3X Shares (FAZ) was 0.3% lower. Carlyle Group ( CG ) was up more than 1%...
Sector Update: Health Care
Sector Update: Health Care
Jun 20, 2024
08:58 AM EDT, 06/20/2024 (MT Newswires) -- Health care stocks were steady pre-bell Thursday as the Health Care Select Sector SPDR Fund (XLV) was down 0.2% while iShares Biotechnology ETF (IBB) was recently unchanged. Jazz Pharmaceuticals ( JAZZ ) was down more than 2% after saying its investigational therapy suvecaltamide did not meet its primary endpoint in a phase 2b...
Copyright 2023-2025 - www.financetom.com All Rights Reserved